Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1169693#aggregation> ?p ?o. }
Showing items 1 to 68 of
68
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B607436.
- aggregation creator B607437.
- aggregation creator B607438.
- aggregation creator B607439.
- aggregation creator B607440.
- aggregation creator B607441.
- aggregation creator B607442.
- aggregation creator B607443.
- aggregation creator B607444.
- aggregation creator B607445.
- aggregation creator B607446.
- aggregation creator B607447.
- aggregation creator B607448.
- aggregation creator B607449.
- aggregation creator B607450.
- aggregation creator B607451.
- aggregation creator B607452.
- aggregation creator B607453.
- aggregation creator B607454.
- aggregation creator B607455.
- aggregation creator B607456.
- aggregation creator B607457.
- aggregation creator B607458.
- aggregation creator B607459.
- aggregation creator B607460.
- aggregation creator B607461.
- aggregation creator B607462.
- aggregation creator B607463.
- aggregation creator B607464.
- aggregation creator B607465.
- aggregation creator B607466.
- aggregation creator B607467.
- aggregation creator B607468.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1169693.bibtex.
- aggregation hasFormat 1169693.csv.
- aggregation hasFormat 1169693.dc.
- aggregation hasFormat 1169693.didl.
- aggregation hasFormat 1169693.doc.
- aggregation hasFormat 1169693.json.
- aggregation hasFormat 1169693.mets.
- aggregation hasFormat 1169693.mods.
- aggregation hasFormat 1169693.rdf.
- aggregation hasFormat 1169693.ris.
- aggregation hasFormat 1169693.txt.
- aggregation hasFormat 1169693.xls.
- aggregation hasFormat 1169693.yaml.
- aggregation isPartOf urn:issn:0732-183X.
- aggregation language "eng".
- aggregation publisher "AMER SOC CLINICAL ONCOLOGY".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Prognostic impact of gene expression-based classification for neuroblastoma".
- aggregation abstract "Purpose To evaluate the impact of a predefined gene expression - based classifier for clinical risk estimation and cytotoxic treatment decision making in neuroblastoma patients. Patients and Methods Gene expression profiles of 440 internationally collected neuroblastoma specimens were investigated by microarray analysis, 125 of which were examined prospectively. Patients were classified as either favorable or unfavorable by a 144- gene prediction analysis for microarrays (PAM) classifier established previously on a separate set of 77 patients. PAM classification results were compared with those of current prognostic markers and risk estimation strategies. Results The PAM classifier reliably distinguished patients with contrasting clinical courses (favorable [n = 249] and unfavorable [n = 191]; 5- year event free survival [EFS] 0.84 +/- 0.03 v 0.38 +/- 0.04; 5-year overall survival [OS] 0.98 +/- 0.01 v 0.56 +/- 0.05, respectively; both P = .001). Moreover, patients with divergent outcome were robustly discriminated in both German and international cohorts and in prospectively analyzed samples (P = .001 for both EFS and OS for each). In subgroups with clinical low-, intermediate-, and high-risk of death from disease, the PAM predictor significantly separated patients with divergent outcome (low-risk 5-year OS: 1.0 v 0.75 +/- 0.10, P = .001; intermediaterisk: 1.0 v 0.82 +/- 0.08, P = .042; and high-risk: 0.81 +/- 0.08 v 0.43 = 0.05, P=.001). In multivariate Cox regression models based on both EFS and OS, PAM was a significant independent prognostic marker (EFS: hazard ratio [HR], 3.375; 95% CI, 2.075 to 5.492; P=.001; OS: HR, 11.119, 95% CI, 2.487 to 49.701; P=.001). The highest potential clinical impact of the classifier was observed in patients currently considered as non - high- risk (n= 289; 5- year EFS: 0.87= 0.02 v 0.44= 0.07; 5- year OS: 1.0 v 0.80= 0.06; both P=.001). Conclusion Gene expression - based classification using the 144- gene PAM predictor can contribute to improved treatment stratification of neuroblastoma patients.".
- aggregation authorList BK965296.
- aggregation endPage "3515".
- aggregation issue "21".
- aggregation startPage "3506".
- aggregation volume "28".
- aggregation aggregates 1169735.
- aggregation isDescribedBy 1169693.
- aggregation similarTo JCO.2009.27.3367.
- aggregation similarTo LU-1169693.